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Abstract
Risk factors that contribute to inter-individual differences in the age-of-onset of allergic dis-
eases are poorly understood. The aim of this study was to identify genetic risk variants asso-
ciated with the age at which symptoms of allergic disease first develop, considering
information from asthma, hay fever and eczema. Self-reported age-of-onset information
was available for 117,130 genotyped individuals of European ancestry from the UK Biobank
study. For each individual, we identified the earliest age at which asthma, hay fever and/or
eczema was first diagnosed and performed a genome-wide association study (GWAS) of
this combined age-of-onset phenotype. We identified 50 variants with a significant indepen-
dent association (P<3x10-8) with age-of-onset. Forty-five variants had comparable effects
on the onset of the three individual diseases and 38 were also associated with allergic dis-
ease case-control status in an independent study (n = 222,484). We observed a strong neg-
ative genetic correlation between age-of-onset and case-control status of allergic disease
(rg = -0.63, P = 4.5x10-61), indicating that cases with early disease onset have a greater bur-
den of allergy risk alleles than those with late disease onset. Subsequently, a multivariate
GWAS of age-of-onset and case-control status identified a further 26 associations that were
missed by the univariate analyses of age-of-onset or case-control status only. Collectively,
of the 76 variants identified, 18 represent novel associations for allergic disease. We identi-
fied 81 likely target genes of the 76 associated variants based on information from expres-
sion quantitative trait loci (eQTL) and non-synonymous variants, of which we highlight
ADAM15, FOSL2, TRIM8, BMPR2, CD200R1, PRKCQ, NOD2, SMAD4, ABCA7 and
UBE2L3. Our results support the notion that early and late onset allergic disease have partly
distinct genetic architectures, potentially explaining known differences in pathophysiology
between individuals.
Author summary
So far, genetic studies of allergic disease have investigated the presence of the disease
rather than the age at which the first allergic symptoms develop. We aimed to identify
genetic risk variants associated with the age at which symptoms of allergic disease first
develop, considering information from asthma, hay fever and eczema by examining
117,130 genotyped individuals of European ancestry from the UK Biobank study. We
identified 50 variants with a significant independent association (P<3x10-8) with age-of-
onset. Forty-five variants had comparable effects on the onset of the three individual dis-
eases and 38 were also associated with allergic disease case-control status in an indepen-
dent study (n = 222,484). We then performed a multivariate GWAS of age-of-onset and
case-control status identified a further 26 associations that were missed by the univariate
analyses of age-of-onset or case-control status only. 18 of 76 variants identified represent
novel associations for allergic disease. We identified 81 likely target genes of the 76 genetic
variants, including ADAM15, FOSL2, TRIM8, BMPR2, CD200R1, PRKCQ, NOD2,
SMAD4, ABCA7 and UBE2L3. Our results support the notion that early and late
onset allergic disease have partly distinct genetic architectures, potentially explaining
known differences in pathophysiology between individuals.
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Introduction
In the last 10 years, at least 45 genome-wide association studies (GWAS) of allergic disease sus-
ceptibility were published: 25 for asthma (reviewed in [1]), three for hay fever (or allergic rhi-
nitis) [2–4], eight for eczema (or atopic dermatitis) [5–12], four for food allergy [13–16] and
six for allergy-related traits, namely atopic march [17], asthma with hay fever [18], allergies
[19], allergic sensitization [2,20,21] and a combined asthma, hay fever and eczema phenotype
[22]. Genetic risk variants identified in these studies provide a foundation to help us better
understand why and how allergic disease develops in susceptible individuals.
One twin study has previously indicated that the timing of asthma onset may be under
genetic control [23]. In the first genome wide association study for asthma published in 2007, it
was reported that the ORMDL3/GSDMA locus at chromosome 17q12 was specifically associated
with childhood onset asthma[24]. This observation was subsequently confirmed, showing strong
associations of this locus with childhood-onset asthma, potentially interacting with passive ciga-
rette smoke exposure in early childhood [25] or as childhood onset asthma defined as asthma
developing before 16 years of age) but not later onset asthma in the GABRIEL consortium [26]
In subsequent stratified analyses in a multinational study, it was reported that the association of
the 17q risk SNP rs7216389-T was confined to cases with early onset of asthma, particularly in
early childhood (age: 0–5 years) and adolescence (age: 14–17 years), but a weaker association
was observed for onset between 6 and 13 years of age, whereas no association was observed for
adult-onset asthma [27]. This shows that defining cut-offs for age at onset of asthma is difficult,
and that other approaches such as using a continuous age at onset might be beneficial.
To our knowledge, only three studies have reported genetic variants that associate with the
age at which allergic disease symptoms first develop. Forno et al. [28] studied asthma age-of-
onset in 573 children and identified two variants that had a genome-wide significant associa-
tion after combining the discovery and replication (n = 931) cohorts: rs9815663 near the
CRBN gene on chromosome 3p26, and rs7927044 near ETS1 on 11q24. In a more recent
GWAS of 5,462 cases with asthma, Sarnowski et al. [29] identified five variants associated with
age-of-onset, located in/near: CYLD on 16q12 (rs1861760), IL1RL1 on 2q12 (rs10208293),
HLA-DQA1 on 6p21 (rs9272346), IL33 on 9p24 (rs928413) and GSDMA on 17q12
(rs9901146). The latter four variants were previously reported to be associated with allergic
disease susceptibility as well. Lastly, Ferreira et al. [22] reported that 26 of 136 variants associ-
ated with allergic disease risk were also associated with the age at which allergic symptoms first
developed (n = 35,972). Amongst these were five variants for which the association with age-
of-onset was genome-wide significant: rs61816761 in the FLG gene and rs12123821 near
HRNR, both on chromosome 1q21; rs921650 in GSDMB on 17q12; rs10865050 in IL18R1 on
2q12; and rs7936323 near LRRC32 on 11q13. Two of the variants reported in Ferreira et al.
(rs10865050 and rs921650) were in linkage disequilibrium (LD) with variants reported in Sar-
nowski et al., and so are unlikely to represent independent associations. Therefore, collectively
across these three studies, 12 variants (2+5+5, including 10 in low LD with each other) were
reported to associate with age-of-onset of allergic disease at the genome-wide significance
level. Of interest, the joint association between age-at-onset and disease susceptibility at some
of these loci [29] suggests that both phenotypes are genetically correlated, and so that combin-
ing information from both may improve power to identify variants that influence the aetiology
of allergic disease.
The main aim of this study was to identify novel loci that contribute to inter-individual var-
iability in the age at which allergic symptoms first develop, considering information from the
three most common allergic diseases: asthma, hay fever and eczema. Rather than study the
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age-of-onset of each disease separately, we adopted the multi-disease phenotype approach that
we used recently to identify risk variants that are shared across different allergic diseases [22].
Specifically, we determined the earliest age at which asthma and/or hay fever and/or eczema
first developed and then tested this single combined age-of-onset of allergic disease phenotype
in a GWAS. In addition, we also tested if variants associated with disease age-of-onset were
also associated with disease risk, as noted by Sarnowski et al. [29]. Lastly, we used multivariate
association analysis to identify variants jointly associated with allergic disease age-of-onset and
case-control status, which were missed by analyzing each phenotype alone.
Results
Genetic variants associated with the age-of-onset of allergic disease
Our study population consisted of n = 117,130 participants from the UK Biobank study (S2
Table), who had a mean age of 55.5 years (range 38–72 years), with a mean (median) age at
onset of any allergic disease of 26.3 (22 years), defined as the earliest age at which any allergic
disease (asthma, hay fever or eczema) was first reported (see S1 Fig for distribution).
We first performed a GWAS of a combined age-of-onset phenotype (n = 117,130 from the
UK Biobank study. After adjusting the association results (S2 Fig) for the observed LD-score
regression intercept [30] of 1.025, we identified 4,160 variants with a genome-wide significant
association with age-of-onset (P<3x10-8, Fig 1). Of these, 50 variants in 40 loci (i.e. regions >1
Mb apart) remained associated at that threshold after accounting for the effects of adjacent
SNPs in joint association analysis (<10 Mb; Table 1 and S3 Table), indicating that they repre-
sent statistically independent associations with age-of-onset. Henceforth, we refer to these
SNPs as sentinel variants for age-of-onset. Two additional variants had a P<3x10-8 in the joint
but not in the original single-SNP analysis (S4 Table), both located in the major histocompati-
bility complex (MHC) locus. These represent secondary association signals at the MHC that
were masked in the original GWAS by the association with other stronger nearby SNPs.
Three of the 50 sentinel variants were in linkage disequilibrium (LD; r2>0.8) with variants
previously reported to have a genome-wide significant association with asthma age-of-onset
[29]: rs72823628 in IL18R1, rs7848215 near IL33 and rs4795400 in GSDMB. Similarly, an addi-
tional three variants were in LD with SNPs that we reported recently [22] to be associated with
the same combined age-of-onset phenotype: rs61816761 in FLG, rs12123821 near HRNR and
rs11236791 near LRRC32. On the other hand, to our knowledge, the remaining 44 sentinel
Fig 1. Summary of results from the GWAS of allergic disease age-of-onset in the UK Biobank study (n = 117,130). UK
Biobank participants reported age-of-onset for asthma and, in a single separate question, for hay fever/eczema. In this analysis, we
took the earliest age-of-onset reported across these two questionnaire items and tested this phenotype for association with SNP
allelic dosage. We identified 4,160 variants associated with age-of-onset at a P<3x10-8 (red circles), including 50 with a statistically
independent association.
https://doi.org/10.1371/journal.pgen.1008725.g001
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variants have not previously been implicated in the age-of-onset of any allergic disease at the
genome-wide significance level.
Of the 12 specific variants previously reported to associate with allergic disease age-of-
onset, 11 were tested in our current age-of-onset GWAS, of which nine had a highly significant
and directionally concordant association (S5 Table). For two variants, there was no evidence
for association with the combined age-of-onset phenotype: rs1861760 near CYLD (P = 0.41),
reported by Sarnowski et al. [29], and rs9815663 near CRBN (P = 0.67), reported by Forno
et al. [28]. The second variant reported by Forno et al. had a MAF<1% and so it was not tested
in our current age-of-onset GWAS. We did however test this variant ad-hoc and found that it
was not significantly associated with age-of-onset (P = 0.35, not shown).
Potential impact of recall bias and phenotypic misclassification on SNP
associations
All UK Biobank participants included in our analyses were adults (aged 38 to 70) at the time of
data collection, and so recall bias might have affected the reported age-of-onset. Furthermore,
proportionally, there were many individuals who reported late onset of allergic disease (e.g.
41% of asthmatics with onset�40 years old), which could have resulted from recall bias and/
or phenotypic misclassification. We performed an additional set of analyses to determine if
these potential confounders were likely to have had a major impact on the SNP associations
described above. We addressed reliability of the age-of-onset information by comparing the
self-reported age-of-onset between two surveys that were between 4–7 years apart. Age of
onset was within 5 years accurate in 86% of cases. Subjects that reported less reliable informa-
tion were likely to be older at enrollment. Older subjects were also less likely to report child-
hood onset asthma. When we analyzed the 50 sentinel variants in subjects who reported
developing asthma as a child, and secondly, rhinitis as a child, we obtained highly consistent
results, see S4A Fig and S4B Fig, respectively. We also replicated our findings in a prospective
birth cohort ALSPAC, and show a high correlation of 0.67–0.825 of the effect size of our analy-
sis with the results obtained in the ALSPAC study. Since the ALSPAC study prospectively
assessed asthma, recall bias in this study is not a concern. Moreover, we correlated our findings
for adult-onset asthma with two independent, published datasets of asthma GWAS performed
by the GABRIEL consortium [26] and the TAGC consortium [31], and identified a substantial
genetic correlation of rg of 0.62 and 0.66, respectively. We further correlated our UKBB results
of adult onset asthma with an analysis of adult onset asthma in the HUNT study, and again
observed a significant genetic correlation rg of 0.69. Further details of these analyses are pro-
vided in S1 Data (page 9) and S3 Fig–S6 Fig, and S14 Table.
Association with age-of-onset in individuals suffering from a single allergic
disease
By analyzing an age-of-onset phenotype that considered information from asthma, hay fever
and eczema, the GWAS described above was expected to identify variants that affect age-of-
onset broadly across the three diseases. To formally address this possibility, we tested each of
the 50 sentinel variants identified above for association with the age-of-onset of asthma, hay
fever and eczema, in three separate analyses. Specifically, we analysed age-of-onset in three
non-overlapping groups of individuals (S1 Fig): those who reported suffering only from
asthma (n = 22,029), only from hay fever (n = 14,474) or only from eczema (n = 3,969). Within
each of these groups, we tested the association between the 50 sentinel variants and disease
age-of-onset, using BOLT-LMM. In individuals suffering from asthma only, 19 sentinel vari-
ants were associated with variation in age-of-onset at P<3.3x10-4 (43 at P<0.05), which
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Table 1. Variants independently associated with allergic disease age-of-onset at a P<3x10-8.
Chr Bp Sentinel SNP Gene context Association with allergic disease age-of-onset
(n = 117,130)
Novel association for allergic disease
Effect allele Freq# Beta SE P-value
1 152029548 rs115045402 S100A11-[]-TCHHL1 A 0.028 -0.202 0.014 1.7e-47 No
1 153051661 rs184587444 [SPRR2A] T 0.020 -0.191 0.017 3.8e-28 Yes
1 155142927 rs4971089 [KRTCAP2] G 0.488 -0.024 0.004 1.6e-08 Yes
1 172715702 rs78037977 FASLG-[]—TNFSF18 A 0.879 -0.044 0.006 1.1e-11 No
1 173141960 rs7521390 TNFSF18—[]-TNFSF4 C 0.296 -0.031 0.005 2.2e-11 No
2 8451701 rs13398375 [LINC00299] T 0.716 -0.029 0.005 7.5e-10 No
2 28644670 rs7559046 FOSL2-[]-PLB1 C 0.537 -0.031 0.004 3.1e-13 No
2 228670437 rs10187276 SLC19A3-[]-CCL20 T 0.256 -0.034 0.005 4.6e-13 No
2 242698640 rs34290285 [D2HGDH] G 0.757 -0.036 0.005 2.6e-13 No
3 188132110 rs6780858 [LPP] G 0.524 -0.031 0.004 1.3e-13 No
4 38792340 rs6531663 TLR10-[]-TLR1 T 0.808 -0.067 0.005 2.6e-38 No
4 103515055 rs4648052 [NFKB1] G 0.633 -0.025 0.004 7.0e-09 No
4 123141070 rs45613035 [KIAA1109] C 0.104 -0.038 0.007 2.2e-08 No
4 123403008 rs45610037 IL2-[]—IL21 A 0.227 -0.042 0.005 1.5e-17 No
5 110164674 rs7728612 SLC25A46-[]—TSLP T 0.167 -0.045 0.006 9.9e-16 No
5 110470137 rs6594499 WDR36-[]-CAMK4 C 0.530 -0.029 0.004 4.5e-12 No
5 132028858 rs4705962 [KIF3A] T 0.234 -0.031 0.005 2.4e-10 No
6 31323012 rs2854001 [HLA-B] A 0.237 -0.035 0.005 4.5e-13 No
6 32626015 rs6905282 HLA-DQA1-[]-HLA-DQB1 A 0.466 -0.042 0.004 1.1e-23 No
6 33033710 rs73739621 [HLA-DPA1] C 0.096 -0.051 0.008 3.7e-11 No
7 50325815 rs2085423 C7orf72—[]-IKZF1 A 0.248 -0.035 0.005 4.1e-13 No
9 136155000 rs635634 ABO-[]-SURF6 T 0.189 -0.031 0.005 1.1e-08 No
10 104285594 rs12572775 [SUFU] A 0.447 -0.033 0.004 7.6e-15 No
11 65559266 rs10791824 [OVOL1] G 0.575 -0.035 0.004 1.8e-16 No
11 76299431 rs55646091 WNT11—[]-LRRC32 A 0.056 -0.089 0.009 4.7e-22 No
11 118746769 rs4938576 DDX6-[]-CXCR5 G 0.592 -0.028 0.004 2.1e-11 No
11 128161142 rs61907712 KIRREL3-AS3—[]—ETS1 C 0.813 -0.034 0.005 1.8e-10 No
12 56384804 rs705699 [RAB5B] A 0.432 -0.025 0.004 3.6e-09 No
12 57493727 rs3024971 [STAT6] T 0.900 -0.044 0.007 3.3e-10 No
12 111973358 rs597808 [ATXN2] G 0.523 -0.033 0.004 1.9e-15 No
12 121202664 rs9431 [SPPL3] A 0.497 -0.028 0.004 2.4e-11 No
13 43034968 rs1853573 AKAP11—[]—TNFSF11 G 0.465 -0.029 0.004 4.2e-12 No
14 68760527 rs7140939 [RAD51B] A 0.403 -0.027 0.004 1.9e-10 No
14 103256961 rs56101042 [TRAF3] A 0.820 -0.036 0.005 2.6e-11 No
15 61069988 rs11071559 [RORA] C 0.877 -0.042 0.006 5.3e-11 No
15 67455630 rs56062135 [SMAD3] T 0.247 -0.029 0.005 2.7e-09 No
15 90936225 rs2601191 [IQGAP1] T 0.473 -0.028 0.004 1.9e-11 No
16 11229589 rs2041733 [CLEC16A] T 0.447 -0.031 0.004 2.2e-13 No
17 38756969 rs7216890 CCR7-[]-SMARCE1 T 0.654 -0.033 0.004 7.2e-14 No
18 51780408 rs3017289 MBD2-[]-POLI C 0.289 -0.029 0.005 2.4e-10 No
18 60009814 rs4574025 [TNFRSF11A] T 0.540 -0.032 0.004 2.7e-14 No
18 61442619 rs12964116 [SERPINB7] G 0.037 -0.108 0.011 6.2e-23 No
19 8785744 rs2918302 ADAMTS10—[]-ACTL9 A 0.156 -0.038 0.006 5.4e-11 No
20 45689783 rs4809619 [EYA2] G 0.752 -0.029 0.005 3.7e-09 Yes
1 152179152 rs12123821 RPTN-[]-HRNR T 0.051 -0.138 0.009 2.9e-48 No
(Continued)
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corrects for 50 SNPs tested in 3 groups, despite the smaller sample size of this analysis (S6
Table). For hay fever and eczema, there were respectively 8 and 5 SNPs associated with age-of-
onset at that significance threshold (24 and 12 at P<0.05). Of note, the directional effect
observed with the combined phenotype was the same as in the single disease analyses for most
sentinel variants (100% for asthma, 94% for hay fever and 80% for eczema).
Lastly, when we formally compared the effect of each sentinel variant on age-of-onset (i.e.
the beta from the linear model) between pairs of diseases, we found that most variants (45 of
50, 90%) did not have significant disease-specific effects on age-of-onset (all pairwise compari-
sons with P>3.3x10-4; S6 Table). The exceptions were four variants located on chromosomes
1q21.3 (in/near TCHHL1, HRNR, FLG and SPRR2A) which had significantly stronger effects
on age-of-onset of eczema, and one on 17q12 (in GSDMB) which had a stronger effect on the
age-of-onset of asthma (Fig 2). Therefore, we conclude that most (45 of 50) sentinel variants
identified in the GWAS of the combined age-of-onset phenotype have similar effects when
considering the age-of-onset separately for asthma, hay fever and eczema.
Association between age-of-onset sentinel variants and allergic disease risk
We then asked if the 50 sentinel variants were also likely to influence the risk of developing
allergic disease, in addition to contributing to variation in age-of-onset amongst affected indi-
viduals. To this end, we investigated the association between each sentinel variant and a com-
bined allergic disease phenotype, as reported in our recent GWAS [22]. After excluding the
UK Biobank study from that GWAS, association results were based on data from 137,883 cases
with asthma and/or hay fever and/or eczema, and 84,601 disease-free controls. Forty-eight of
the 50 sentinel variants were tested in that GWAS, either directly or via a proxy (one variant),
of which 38 (or 79%) were significantly associated with disease risk (P<0.001, which corrects
for 48 tests; Table 2). This includes 19 variants for which the association with disease risk was
genome-wide significant (P<3x10-8); that is, variants that represent previously known risk fac-
tors for allergic disease. Notably, for all 48 variants tested, the allele associated with a higher
disease risk was associated with a lower age-of-onset. Therefore, we conclude that the sentinel
variants identified influence both the likelihood of developing any allergic disease as well as
the age at which symptoms first develop.
Genetic correlation between age-of-onset and disease case-control status
For all 50 sentinel age-of-onset variants, the allele that was associated with a lower age-of-onset
was associated with a higher risk of allergic disease. This observation suggested that these two
traits–age-of-onset and case-control status of allergic disease–have a substantial negative
Table 1. (Continued)
Chr Bp Sentinel SNP Gene context Association with allergic disease age-of-onset
(n = 117,130)
Novel association for allergic disease
Effect allele Freq# Beta SE P-value
1 152285861 rs61816761 [FLG] A 0.026 -0.266 0.014 2.8e-82 No
2 102928617 rs72823628 [IL18R1] G 0.874 -0.076 0.006 2.4e-33 No
9 6213468 rs7848215 RANBP6—[]-IL33 T 0.273 -0.029 0.005 7.5e-10 No
11 76295598 rs11236791 WNT11—[]-LRRC32 A 0.469 -0.046 0.004 3.8e-28 No
17 38067020 rs4795400 [GSDMB] C 0.541 -0.050 0.004 6.0e-33 No
# Frequency of effect allele in the allergic disease cases studied.
https://doi.org/10.1371/journal.pgen.1008725.t001
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genetic correlation; to our knowledge, this has not been previously estimated. To understand
the extent to which the same genetic variants contribute to variation in these two traits, we
applied LD-score regression [30] to the summary statistics of our age-of-onset and allergic dis-
ease [22] GWAS. Based on 1.1 million common SNPs, the genetic correlation between the two
traits was estimated to be -0.625 (SE = 0.038, P = 4.5x10-61). This estimate was not expected to
be biased by the sample overlap between the two GWAS [32], which we confirmed when we
excluded samples from the UK Biobank study from the allergic disease [22] GWAS (rg =
-0.612, SE = 0.046, P = 5.0x10-41). These results indicate that a substantial fraction of genetic
variants are likely to influence both the liability to, and the age-of-onset of, allergic disease.
Furthermore, for most (but not necessarily all) shared variants, the directional effect is such
that variants that are associated with higher disease risk are associated with lower age-of-onset.
More broadly, these results strongly suggest that a key risk factor that distinguishes individ-
uals with early disease onset from those with late disease onset is the overall genetic burden
inherited at allergy-associated SNPs. To illustrate this effect, we compared the distribution of
Fig 2. Variants with evidence for disease-specific effects on age-of-onset. Each of the 50 variants identified in the GWAS of age-of-onset were tested for
association with age-of-onset in three non-overlapping groups of individuals: those suffering from asthma only (n = 22,029), hay fever only (n = 14,474) and
eczema only (n = 3,969). We then compared the effects (i.e. betas) obtained in these three groups. For 5 of the 50 variants (shown with an orange inner
triangle), the effect on age-of-onset was significantly different (P<0.05/(3 x 50) = 3.3x10-4) between at least two groups. For a given variant, the vertices of
the inner triangle point to the position along the edges of the outer triangle that corresponds to difference in effect observed between pairs of single-disease
cases. For example, the rs61816761[A] allele, which is located in the FLG gene (filaggrin), had an effect on age-of-onset that was larger (absolute of
difference = 0.42) in individuals suffering only from eczema when compared to individuals suffering only from hay fever (P = 4.3x10−8), consistent with this
SNP having a stronger effect on the age-of-onset of eczema than of hay fever. For comparison, a variant with no significant differences when comparing the
effect on age-of-onset in all three pairwise single-disease association analyses is also shown (rs705699, in the RAB5B gene). In this case, the difference in
effect was approximately equal to 0 in the three pairwise comparisons. The color of the difference in effect reflects the significance of the corresponding z-
score (see Methods): red for P< 3.2x10−4 (correction for multiple testing), blue for P<0.05 and black for P>0.05.
https://doi.org/10.1371/journal.pgen.1008725.g002
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Table 2. Association between sentinel age-of-onset variants and allergic disease risk in an independent sample of 222,484 individuals studied by Ferreira et al. [22].
Chr Bp Sentinel SNP Gene context Association with allergic disease risk in Ferreira et al. 2017
(n = 222,484)�
Effect allele Odds ratio SE P-value
1 152029548 rs115045402 S100A11-[]-TCHHL1 NA NA NA NA
1 152179152 rs12123821 RPTN-[]-HRNR T 1.091 0.019 2.40E-06
1 152285861 rs61816761 [FLG] A 1.26 0.036 8.90E-11
1 153051661 rs184587444 [SPRR2A] NA NA NA NA
1 155142927 rs4971089 [KRTCAP2] G 1.006 0.007 3.50E-01
1 172715702 rs78037977 FASLG-[]—TNFSF18 A 1.051 0.011 6.70E-06
1 173141960 rs7521390 TNFSF18—[]-TNFSF4 C 1.047 0.008 7.90E-10
2 8451701 rs13398375 [LINC00299] T 1.063 0.008 1.20E-15
2 28644670 rs7559046� FOSL2-[]-PLB1 C 1.034 0.007 3.50E-06
2 102928617 rs72823628 [IL18R1] G 1.123 0.01 3.50E-32
2 228670437 rs10187276 SLC19A3-[]-CCL20 T 1.034 0.008 5.70E-05
2 242698640 rs34290285 [D2HGDH] G 1.08 0.011 2.00E-13
3 188132110 rs6780858 [LPP] G 1.036 0.007 5.00E-07
4 38792340 rs6531663 TLR10-[]-TLR1 T 1.088 0.008 3.30E-26
4 103515055 rs4648052 [NFKB1] G 1.036 0.007 8.70E-07
4 123141070 rs45613035 [KIAA1109] C 1.05 0.013 9.50E-05
4 123403008 rs45610037 IL2-[]—IL21 A 1.069 0.008 6.20E-16
5 110164674 rs7728612 SLC25A46-[]—TSLP T 1.066 0.009 1.80E-12
5 110470137 rs6594499 WDR36-[]-CAMK4 C 1.073 0.007 1.70E-24
5 132028858 rs4705962 [KIF3A] T 1.047 0.008 2.30E-08
6 31323012 rs2854001 [HLA-B] A 1.061 0.009 5.30E-11
6 32626015 rs6905282 HLA-DQA1-[]-HLA-DQB1 A 1.063 0.007 3.70E-17
6 33033710 rs73739621 [HLA-DPA1] C 1.06 0.013 1.10E-05
7 50325815 rs2085423 C7orf72—[]-IKZF1 A 1.017 0.008 3.60E-02
9 6213468 rs7848215 RANBP6—[]-IL33 T 1.07 0.008 3.80E-18
9 136155000 rs635634 ABO-[]-SURF6 T 1.039 0.009 9.60E-06
10 104285594 rs12572775 [SUFU] A 1.015 0.007 2.60E-02
11 65559266 rs10791824 [OVOL1] G 1.033 0.007 6.30E-06
11 76295598 rs11236791 WNT11—[]-LRRC32 A 1.088 0.007 3.70E-34
11 76299431 rs55646091 WNT11—[]-LRRC32 A 1.188 0.018 1.10E-22
11 118746769 rs4938576 DDX6-[]-CXCR5 G 1.037 0.007 2.30E-07
11 128161142 rs61907712 KIRREL3-AS3—[]—ETS1 C 1.041 0.009 5.60E-06
12 56384804 rs705699 [RAB5B] A 1.039 0.007 6.80E-08
12 57493727 rs3024971 [STAT6] T 1.083 0.012 4.00E-12
12 111973358 rs597808 [ATXN2] G 1.029 0.007 3.50E-05
12 121202664 rs9431 [SPPL3] A 1.028 0.007 4.50E-05
13 43034968 rs1853573 AKAP11—[]—TNFSF11 G 1.017 0.007 1.20E-02
14 68760527 rs7140939 [RAD51B] A 1.033 0.008 1.60E-05
14 103256961 rs56101042 [TRAF3] A 1.026 0.009 2.90E-03
15 61069988 rs11071559 [RORA] C 1.055 0.01 5.30E-08
15 67455630 rs56062135 [SMAD3] T 1.062 0.008 1.70E-13
15 90936225 rs2601191 [IQGAP1] T 1.023 0.007 1.40E-03
16 11229589 rs2041733 [CLEC16A] T 1.05 0.007 1.10E-12
17 38067020 rs4795400 [GSDMB] C 1.066 0.007 5.70E-21
17 38756969 rs7216890 CCR7-[]-SMARCE1 T 1.026 0.007 2.00E-04
(Continued)
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age-of-onset between individuals with the highest (top 10%) and the lowest (bottom 10%)
polygenic risk score (PRS) for allergic disease, constructed for each individual from the UK
Biobank study based on information from 136 allergy risk variants that we reported recently
[22]. This analysis was performed separately for asthma, hay fever and eczema, using the same
single-disease case groups described above. For asthma, individuals with the lowest genetic
burden of allergic disease (n = 2,202) had a median age-of-onset of 39 years, with only 14%
having an age-of-onset before the age of 16; the distribution of age-of-onset was broadly con-
sistent with a pattern of late disease onset (Fig 3). In contrast, in the group with the highest
genetic burden (n = 2,203), the median age-of-onset decreased to 29 years, with 35% of indi-
viduals reporting that asthma was diagnosed before the age of 16. In this group, there was a
clear shift in the distribution of age-of-onset towards a pattern of early disease onset. Similar
results were observed for hay fever and eczema (Fig 3). Collectively, our results indicate that
genetic risk factors for allergic disease are enriched in cases with early disease onset when com-
pared to those with late disease onset.
Multivariate GWAS of allergic disease case-control status and age-of-onset
The high genetic correlation observed between case-control status and age-of-onset of allergic
disease suggests that a large number of variants contribute to the heritability of both traits. We
therefore hypothesized that multivariate association analysis would identify variants jointly
associated with both traits that were missed in the single-trait analyses. To this end, we first
adjusted the single-SNP results obtained in the age-of-onset and case-control [22] GWAS for
the effects of the sentinel variants identified in the respective study. In the two resulting
adjusted GWAS, there were no variants with an association significant at a P<3x10-8, as
expected (S6 Fig and S7 Fig). There was, however, an excess of significant associations when
compared to the number expected by chance given the number of SNPs tested (S8 Fig and S9
Fig). Many of these associations are likely to represent true positive findings that do not reach
the stringent genome-wide significance threshold in each of those two univariate analyses. To
help identify these, we then performed multivariate analysis of age-of-onset and case-control
status, using metaUSAT [33], which is applicable to association summary statistics. Using this
approach, we identified 281 variants with a multivariate P<3x10-8 (Fig 4 and S11 Fig), includ-
ing 26 that were in low LD with each other (r2<0.05) and so that are likely to represent statisti-
cally independent associations (Table 3). However, the QQ Plots may indicate some inflation
of the P values, so therefore, these data need to be interpreted with caution. The genomic
Table 2. (Continued)
Chr Bp Sentinel SNP Gene context Association with allergic disease risk in Ferreira et al. 2017
(n = 222,484)�
Effect allele Odds ratio SE P-value
18 51780408 rs3017289 MBD2-[]-POLI C 1.013 0.008 7.40E-02
18 60009814 rs4574025 [TNFRSF11A] T 1.028 0.007 4.80E-05
18 61442619 rs12964116 [SERPINB7] G 1.04 0.021 6.00E-02
19 8785744 rs2918302 ADAMTS10—[]-ACTL9 A 1.023 0.01 1.50E-02
20 45689783 rs4809619 [EYA2] G 1.013 0.008 9.70E-02
# Association results from 12 of the 13 individual studies reported in the Ferreira et al. 2017 allergic disease GWAS were included in this analysis (all except UK
Biobank). Results from the individual studies were adjusted for the respective study-specific LD-score intercept and then combined using a fixed-effects meta-analysis,
as described previously [22]. The LD-score intercept of this 12-study meta-analysis was 1.018 (attenuation ratio of 0.0717)
� rs7559046 was not directly tested in the Ferreira et al. 2017 GWAS, and so we used a proxy instead (rs6547850, r2 = 0.93).
https://doi.org/10.1371/journal.pgen.1008725.t002
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inflation factor could not be calculated because metaUSAT does not have a closed form null
distribution. Nonetheless, inflation of significant associations can be assessed by comparing
the observed and expected number of associations significant at a given significance threshold.
We observed 38%, 17%, 10%, 5.9% and 1.9% of SNPs tested with a multivariate P-value <0.5,
Fig 3. Distribution of allergic disease age-of-onset as a function of a polygenic risk score (PRS) for allergic disease in UK Biobank
participants who reported suffering from a single disease (asthma only, hay fever only and eczema only). The PRS of each individual was
calculated based on 136 SNPs that were associated with allergic disease risk in our recent GWAS [22]. The mean and median of each
distribution are shown in red and blue, respectively.
https://doi.org/10.1371/journal.pgen.1008725.g003
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Fig 4. Summary of results from the multivariate analysis of allergic disease age-of-onset and allergic disease case-control
status. The GWAS of allergic disease age-of-onset was performed in the UK Biobank study (n = 117,130) as described in the main
text. The GWAS of allergic disease case-control status included 360,838 individuals, has reported recently [22]. Single-SNP results
from each GWAS were adjusted for the top independent associations (P<3x10-8) identified and then multivariate analysis was
performed using metaUSAT [33]. We identified 281 variants with a multivariate P<3x10-8 (red circles), including 26 that were in
low LD (r2<0.05) with each other and so that are likely to represent statistically independent associations.
https://doi.org/10.1371/journal.pgen.1008725.g004
Table 3. Variants jointly associated with allergic disease age-of-onset and allergic disease risk (multivariate P<3x10-8).
Chr Bp Sentinel SNP Gene Context metaUSAT P-value Effect
allele and
frequency
Association with allergic
disease age-of-onset
(n = 117,130)
Association with
allergic disease risk in
Ferreira et al. 2017
(n = 360,838)
Novel
Beta SE P Beta SE P
1 2510755 rs10910095 TNFRSF14-[]-FAM213B 1.62e-08 G 0.868 -0.017 0.006 6.0e-03 0.041 0.007 4.3e-08 No
1 212864992 rs12068304 [BATF3] 2.32e-10 G 0.166 -0.026 0.006 3.9e-06 0.035 0.007 5.8e-07 Nos
2 30846848 rs7565907 [LCLAT1] 6.66e-09 T 0.609 -0.017 0.004 5.5e-05 0.025 0.005 1.4e-06 Yes
2 37137123 rs112844988 [STRN] 2.48e-08 G 0.368 -0.020 0.004 2.2e-06 0.02 0.005 1.4e-04 Yes
2 112268732 rs143326447 BCL2L11—[]—ANAPC1 8.22e-11 C 0.123 -0.030 0.006 3.2e-06 0.043 0.008 2.3e-07 No
2 203487023 rs72926957 BMPR2-[]-FAM117B 1.01e-09 G 0.706 -0.023 0.005 4.7e-07 0.023 0.006 2.3e-05 Yes
3 33047662 rs35570272 [GLB1] 1.28e-08 T 0.404 -0.023 0.004 8.2e-08 0.016 0.005 2.3e-03 No
3 56605990 rs6778373 [CCDC66] 1.51e-09 A 0.535 -0.017 0.004 7.5e-05 0.026 0.005 2.2e-07 Yes
3 112643560 rs9870568 [CD200R1] 4.35e-09 C 0.474 -0.016 0.004 1.7e-04 0.026 0.005 3.1e-07 Yes
5 131952222 rs6596086 [RAD50] 1.9e-08 C 0.200 -0.018 0.005 7.5e-04 0.032 0.006 3.4e-07 No
6 209159 rs11242709 []-DUSP22 1.11e-09 T 0.210 -0.029 0.005 4.3e-08 0.024 0.007 3.0e-04 Yes
6 26186200 rs9379832 HIST1H2BE-[]-HIST1H4D 2.15e-08 G 0.26 -0.019 0.005 6.5e-05 0.027 0.006 4.2e-06 Yes
6 32624874 rs28483633 HLA-DQA1-[]-HLA-DQB1 2.77e-08 C 0.838 -0.035 0.007 1.5e-07 0.056 0.019 2.8e-03 No
6 149909491 rs9322188 [GINM1] 2.99e-08 T 0.313 -0.015 0.005 7.3e-04 0.028 0.006 5.7e-07 Yes
10 6625378 rs2255088 [PRKCQ-AS1] 2.35e-10 C 0.335 -0.021 0.004 1.5e-06 0.027 0.006 1.5e-06 No
12 50336638 rs416959 LOC283332-[]-AQP2 2.21e-09 T 0.824 -0.026 0.006 3.4e-06 0.030 0.007 7.2e-06 Yes
16 50745926 rs2066844 [NOD2] 1.13e-09 T 0.049 -0.043 0.010 8.2e-06 0.059 0.012 1.5e-06 No
16 50885211 rs8056255 CYLD-[]—SALL1 3.26e-09 A 0.033 -0.047 0.012 5.5e-05 0.071 0.014 6.8e-07 Yes
17 17624349 rs77904527 [RAI1] 2.17e-09 C 0.147 -0.031 0.006 2.5e-07 0.028 0.007 1.0e-04 Yes
17 40741013 rs12951632 [FAM134C] 1e-09 T 0.719 -0.026 0.005 3.4e-08 0.020 0.006 3.4e-04 No
17 76244926 rs72901762 TMEM235-[]-LOC100996291 1.89e-08 A 0.711 -0.019 0.005 3.5e-05 0.026 0.006 6.7e-06 Yes
18 48558415 rs35014537 [SMAD4] 4.34e-09 G 0.384 -0.018 0.004 3.1e-05 0.025 0.005 1.6e-06 No
19 1170445 rs4807630 [SBNO2] 1.89e-08 T 0.312 -0.020 0.005 1.5e-05 0.026 0.006 1.6e-05 No
20 52258875 rs4811448 ZNF217-[]—SUMO1P1 2.6e-08 C 0.293 -0.017 0.005 2.9e-04 0.028 0.006 1.2e-06 Yes
22 21939675 rs5754217 [UBE2L3] 2.93e-08 T 0.196 -0.015 0.005 3.8e-03 0.034 0.006 1.2e-07 Yes
22 37319947 rs4437064 [CSF2RB] 2.44e-08 G 0.529 -0.009 0.004 3.2e-02 0.028 0.005 3.0e-08 Yes
https://doi.org/10.1371/journal.pgen.1008725.t003
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<0.2,<0.1,<0.05 and<0.01, respectively, when the expectations under the null hypothesis of
no association were 50%, 20%, 5% and 1%. For most variants, the association in each of the
two univariate analyses was one to four orders of magnitude below genome-wide significance,
which was exceeded in the multivariate analysis. For all variants, the allele associated with
higher disease risk was associated with lower age-of-onset. Results obtained with the recently
described MTAG multivariate approach [34] supported the associations identified with
metaUSAT (S7 Table). We conclude that these 26 variants represent risk factors for both the
presence and early onset of allergic disease, which were only detectable when we combined
information from the age-of-onset and case-control GWAS.
Sentinel variants not previously implicated in the aetiology of allergic
disease
We then determined which of the sentinel variants identified in the age-of-onset and multivar-
iate GWAS described above represented novel associations for allergic disease in general, that
is, when considering all previously reported associations with P<5x10-8 for asthma, hay fever,
eczema, food allergy and/or atopy. Of the 50 sentinel variants identified in our age-of-onset
GWAS, 47 were in LD (r2>0.05) with variants previously reported to associate with allergic
disease (S8 Table). The remaining 3 represent novel associations for allergic disease:
rs184587444 in SPRR2A, rs4971089 in KRTCAP2, and rs4809619 in EYA2 (Table 1). On the
other hand, most 15 of the 26 sentinel variants identified in the multivariate GWAS represent
novel associations for allergic disease (Table 1 and S8 Table), including for example
rs7565907 in LCLAT1and rs11242709 near DUSP22. Thus, overall, by considering age-of-
onset information, we identified 18 (3+15) novel genetic associations for allergic disease.
Likely target genes of sentinel variants identified in the age-of-onset and
multivariate GWAS
To help understand how the 76 sentinel variants might influence allergic disease pathophysiol-
ogy, we identified genes for which variation in gene expression and/or protein sequence was
associated/determined by SNPs in LD with the sentinel variants.
We first extracted association summary statistics from 101 published datasets of eQTL
identified in five different broad tissue types relevant for allergic disease (S1 Table). For
each gene and for a given eQTL dataset, we then (i) identified cis eQTL in low LD (r2<0.05)
with each other, which we refer to as “sentinel eQTL”; and (ii) determined if any of the 76 sen-
tinel variants were in high LD (r2>0.8) with a sentinel eQTL. Using this approach, we found
sentinel eQTL in LD with 26 of the 50 (52%) sentinel variants identified in the age-of-onset
GWAS (S9 Table), and with 15 of the 26 (58%) sentinel variants identified in the multivariate
GWAS (S10 Table). The sentinel eQTL implicated respectively 47 and 28 genes (one in com-
mon: HLA-DQB1) as likely targets of the sentinel variants identified in these two GWAS
(Table 4).
Second, we found 21 non-synonymous SNPs in 14 genes that were in high LD (r2>0.8)
with sentinel variants identified in the age-of-onset or multivariate GWAS (S11 Table). This
list included, for example, four non-synonymous SNPs in the CD200R1 gene that were in com-
plete LD (r2 = 1) with the sentinel variant identified in the multivariate GWAS. Of the 14
genes, seven were novel target predictions, that is, they were not identified in the eQTL analy-
sis described above: FLG, EFNA1, SH2B3, TNFRSF14, HIST1H2BE, MLX and YDJC. Overall,
when considering information from eQTL and non-synonymous SNPs, we identified 81 (47
+27+7) likely target genes of the 76 sentinel variants identified in this study.
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Table 4. Genes with a sentinel eQTL (in italic) or non-synonymous SNP (in bold) in LD (r2>0.8) with sentinel variants identified in the age-of-onset or multivariate
GWAS.
Chr Bp Sentinel SNP Gene context LD between sentinel eQTL/non-synonymous SNP and sentinel GWAS SNP
r2 > 0.95 0.80 < r2 � 0.95
Sentinel variants identified in the GWAS of age-of-onset
1 152285861 rs61816761 [FLG] FLG -
1 155142927 rs4971089 [KRTCAP2] - ADAM15, EFNA1
1 173141960 rs7521390 TNFSF18—[]-TNFSF4 TNFSF4 -
2 28644670 rs7559046 FOSL2-[]-PLB1 - FOSL2,RP11-373D23.3
2 102928617 rs72823628 [IL18R1] MFSD9 IL18RAP,IL1RL1
2 228670437 rs10187276 SLC19A3-[]-CCL20 CCL20 -
3 188132110 rs6780858 [LPP] - BCL6
4 38792340 rs6531663 TLR10-[]-TLR1 TLR1 -
4 103515055 rs4648052 [NFKB1] - NFKB1
4 123403008 rs45610037 IL2-[]—IL21 KIAA1109 -
5 110470137 rs6594499 WDR36-[]-CAMK4 - CAMK4,CTC-551A13.2,TSLP,WDR36
5 132028858 rs4705962 [KIF3A] - KIF3A
6 31323012 rs2854001 [HLA-B] - HLA-C
6 33033710 rs73739621 [HLA-DPA1] - HLA-DPA1,HLA-DPB1,HLA-DQB1,TAPBP
10 104285594 rs12572775 [SUFU] - ACTR1A,C10orf32,SUFU,TMEM180,TRIM8
11 65559266 rs10791824 [OVOL1] EFEMP2,OVOL1,SNX32 -
12 56384804 rs705699 [RAB5B] RPS26,SUOX -
12 57493727 rs3024971 [STAT6] NAB2,STAT6 -
12 111884608 rs597808 [ATXN2] SH2B3 -
12 121202664 rs9431 [SPPL3] SPPL3 OASL
13 43034968 rs1853573 AKAP11—[]—TNFSF11 TNFSF11 -
15 61069988 rs11071559 [RORA] - RP11-554D20.1
15 67455630 rs56062135 [SMAD3] AAGAB -
15 90936225 rs2601191 [IQGAP1] - IQGAP1
17 38067020 rs4795400 [GSDMB] GSDMB GSDMB,IKZF3,ORMDL3,ZPBP2
17 38756969 rs7216890 CCR7-[]-SMARCE1 SMARCE1 -
18 60009814 rs4574025 [TNFRSF11A] PIGN -
18 61442619 rs12964116 [SERPINB7] SERPINB7 -
Sentinel variants identified in the multivariate GWAS of age-of-onset and case-control status
1 2510755 rs10910095 TNFRSF14-[]-FAM213B TNFRSF14 -
2 30846848 rs7565907 [LCLAT1] - LCLAT1
2 37137123 rs112844988 [STRN] STRN -
2 203487023 rs72926957 BMPR2-[]-FAM117B BMPR2,FAM117B -
3 56605990 rs6778373 [CCDC66] CCDC66,FAM208A -
3 112643560 rs9870568 [CD200R1] CD200R1 -
5 131952222 rs6596086 [RAD50] SLC22A5 -
6 26186200 rs9379832 HIST1H2BE-[]-HIST1H4D - HIST1H2BE
6 32624874 rs28483633 HLA-DQA1-[]-HLA-DQB1 HLA-DQA1,HLA-DQB1,HLA-DQB2 HLA-DQA1
6 149909491 rs9322188 [GINM1] PCMT1 GINM1,LATS1,NUP43
10 6625378 rs2255088 [PRKCQ-AS1] PRKCQ -
16 50745926 rs2066844 [NOD2] NOD2 -
16 50885211 rs8056255 CYLD-[]—SALL1 - NOD2
17 40741013 rs12951632 [FAM134C] FAM134C,MLX,PSMC3IP BECN1
17 76244926 rs72901762 TMEM235-[]-LOC100996291 RP11-219G17.4 THA1P
(Continued)
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Association between the 76 sentinel variants and the risk of food allergy
Finally, we tested if the sentinel variants identified above were associated with food allergy
case-control status, in children and adults separately. Although the discovery analysis that
identified the sentinel variants for age of onset of allergy did not include food allergy, we
hypothesized that these sentinel variants may also relate to food allergy. First, we extracted
association results from GWAS that we published recently [15], comprising 497 children with
food allergy diagnosed by oral food challenge in the GOFA study and 2,387 controls. This
study comprised a highly selected group of children with early onset food allergy (mean age at
diagnosis was 2.1 years). In that GWAS, nine of the 76 sentinel variants were significantly asso-
ciated with food allergy after correcting for multiple testing (P<0.05/76 = 0.00065; S13 Table),
namely those in/near FLG (four variants), KIF3A, LRRC32, RAD50, CYLD, and SERPINB7.
Overall, there was a very close agreement in SNP associations between the age-of-onset and
food allergy analyses (S12 Fig); for example, for 66 of 76 variants the allele associated with a
lower age-of-onset onset was associated with a higher disease risk (binomial test P = 2x10-12).
To assess the association between the 76 sentinel variants and food allergy risk in adults, we
extracted association results from a GWAS of self-reported food allergy conducted in the adult
GERA cohort [16], which included 5,108 subjects with self-reported food allergy, of whom
1,104 were admitted to hospital because of food allergy and 23,945 controls who did not report
to have food allergy. In this GWAS, we compared the 1,104 subjects admitted to hospital
because of food allergy to the 23.945 controls. No single variant was significantly associated
with food allergy after correcting for multiple testing (S13 Table). Across the 72 variants tested
in both the child and adult food allergy GWAS, only 43 (60%) had a directionally consistent
association, reflecting very little agreement between results from the two analyses. Overall, our
results show that many variants associated with allergic disease age-of-onset also represent
genetic risk factors for food allergy in young children but not (or less so) in adults. Moreover,
the self-report of food allergy in the adult population is more subject to misclassification and
may also have contributed to this latter observation.
Discussion
In this study, we identified (i) 50 variants associated with allergic disease age-of-onset; (ii) a
significant negative genetic correlation between allergic disease age-of-onset and case-control
status; (iii) 26 additional variants jointly associated with allergic disease age-of-onset and case-
control status; (iv) 81 genes that are likely targets of sentinel variants identified in the age-of-
onset or multivariate GWAS; and (v) nine variants (out of the 76) that are also associated with
the risk of food allergy in young children.
Amongst the 50 associations for allergic disease age-of-onset, six were reported in previous
studies of age-of-onset [28,29], but the remaining 44 were novel associations for this pheno-
type. Conversely, of the 12 variants reported in previous studies, nine were associated in our
GWAS, but three were not (in/near CYLD/NOD2 [29], CRBN [28] and ETS1 [28]). Possible
explanations for the lack of association with these three variants in our GWAS is that their
Table 4. (Continued)
Chr Bp Sentinel SNP Gene context LD between sentinel eQTL/non-synonymous SNP and sentinel GWAS SNP
r2 > 0.95 0.80 < r2 � 0.95
18 48558415 rs35014537 [SMAD4] RP11-729L2.2,SMAD4 -
19 1170445 rs4807630 [SBNO2] - ABCA7
22 21939675 rs5754217 [UBE2L3] CCDC116,UBE2L3 YDJC
https://doi.org/10.1371/journal.pgen.1008725.t004
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effect on age-of-onset is population specific or specific to asthma, the disease considered in the
original studies. However, the three variants were also not significantly associated with age-of-
onset when we restricted our analysis to cases who suffered only from asthma (P = 0.17,
P = 0.64 and P = 0.26, respectively), which suggests that disease-specific effects are unlikely to
explain the discordance.
When we compared the effect of the 50 variants on the age-of-onset of each of the three
individual diseases, we found significant differences only for five variants. Four of these had a
stronger effect on the age-of-onset of eczema: those in/near HRNR (rs1213821), FLG
(rs61816761), TCHHL1 (rs115045402), SPRR2A (rs184587444), all within a 1 Mb locus on
chromosome 1q21. The former two represent known risk factors for allergic disease, with a
stronger effect on eczema [22], consistent with our results. On the other hand, the latter two
variants, which are relatively uncommon (MAF of 2.8% and 2.0%), have not previously been
established as risk factors for allergic disease, although our results for age-of-onset suggest that
this is very likely to be the case. We did not find any eQTL in LD with either variant; on the
other hand, both variants are in low to moderate LD with rs558269137 (r2 = 0.46 and 0.24,
respectively), which encodes the FLG 2282del4 mutation that is associated with eczema and
ichthyosis vulgaris [35]. It is therefore possible that at one (or both) of these variants are tag-
ging that mutation, which was not tested in our study. The fifth variant, rs4795400 in GSDMB,
showed a stronger effect on the age-of-onset of asthma. This variant is in high LD (r2>0.8)
with variants reported to associate with earlier age-of-onset for asthma (rs9901146) [29] and
which are stronger risk factors for asthma when compared to hay fever and eczema (rs921650)
[22], consistent with our results. For the remaining 45 variants identified in our GWAS, our
results suggest that their effect on age-of-onset is comparable between the three individual
diseases.
We also investigated if the 50 variants that determined variation in age-of-onset amongst
allergic disease cases also contributed to differences in case-control status amongst an inde-
pendent sample of 222,484 individuals not part of the UK Biobank that we studied recently
[22]. Remarkably, 39 of 48 variants with available results had a significant association with
case-control status after accounting for multiple testing. Furthermore, for all 39 variants (and
also for the other nine tested), the disease-predisposing allele was associated with a lower age-
of-onset. These results suggested that case-control status and age-of-onset have a strong nega-
tive genetic correlation, which we confirmed (rg = -0.63) using genome-wide SNP data. We
highlight two implications that arise from this observation.
First, this observation confirms that many genetic variants, including those identified in
our age-of-onset GWAS, determine both the lifetime risk of developing an allergic disease as
well as the age at which symptoms first develop. As such, combining information from these
two phenotypes can help identify variants that influence disease liability, as suggested previ-
ously [29]. Motivated by this prediction, we performed multivariate analysis of results from
our GWAS of age-of-onset and our recently published GWAS of allergic disease case-control
status, which also considered information from asthma, hay fever and eczema. Importantly,
we used a multivariate approach (metaUSAT [33]) that was expected to increase power to
detect an association with a variant that influences both traits, when compared to other meth-
ods that are also applicable to GWAS summary statistics (e.g. metaCCA [36]). In this analysis,
we identified 26 variants that were missed by the individual GWAS, highlighting the substan-
tial gain in power that can be obtained by combining information from age-of-onset and case-
control status. Of these 26 variants, only six were in LD (r2>0.05) with variants previously
reported in GWAS of allergic disease. Therefore, most represent new associations for both
age-of-onset and disease risk. Since we were not able to formally replicate these findings in an
independent study, we emphasize the importance of future studies to replicate our results. We
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also suggest that this approach could be extended to include other phenotypes that can be
shown to have a significant genetic correlation with disease risk; for example, these could be
disease severity or markers of allergic sensitization.
Second, the large negative genetic correlation between case-control status and age-of-onset
indicates that for most variants associated with both traits, the allele that is more common in
allergic disease cases (when compared to controls) is also more common in cases with early
onset disease (when compared to those with late onset disease). That is, individuals who
inherit a larger overall burden of allergy-predisposing alleles are more likely to have early
onset disease when compared to those who inherit a lower genetic burden, consistent with pre-
vious findings [37]. This shows that allergic disease risk alleles are more common in early
onset disease, which might imply that allergic disease with late onset is less heritable (i.e. more
‘environmental’) than allergic disease with early onset. For example, it is conceivable that in
late onset disease, environmental (more than genetic) risk factors dysregulate the expression of
genes that play a key role in disease pathophysiology through epigenetic mechanisms, as we
suggested recently [22]. But that may not necessarily be the case. Instead, it is possible that
individuals develop late onset disease because they inherit risk alleles that influence asthma,
hay fever and/or eczema pathophysiology through mechanisms that are not shared with early
onset disease. Studies that address these possibilities are warranted. It is also important to high-
light that we cannot rule out the possibility that recall bias might have contributed to the nega-
tive genetic correlation observed between age-of-onset and case-control status. This might
have occurred if recall bias was less common amongst subjects who reported a younger age of
onset.
We used information from eQTL studies and non-synonymous SNPs to identify 81 genes
that are likely targets of 48 of the 76 (63%) variants identified in either the age-of-onset or mul-
tivariate GWAS performed. In the S1 Data (page 10–15), we discuss in greater detail 10 genes
that are plausible targets of novel allergic disease variants identified in our study and that have
a known function that is directly relevant to disease pathophysiology. In brief, the 10 genes are:
ADAM15, a metalloproteinase which cleaves the toll like receptor adaptor molecule TRIF [38]
and the low affinity IgE receptor [39]; FOSL2, a regulator of cell proliferation involved in B
cell, Th17 cell and epidermal differentiation and function [40–42]; TRIM8, a ligase involved in
post-translational modifications of proteins, including ubiquitination of TAK1 [43] and TRIF
[44]; BMPR2, a receptor for the TGF-beta superfamily [45] that inhibits Smad-mediated sig-
naling [46]; CD200R1, a surface glycoprotein that interacts with CD200 [47], which is known
to suppress the activation of various immune cells, including macrophages [48], mast cells
[49], monocytes [50] and dendritic cells [51]; PRKCQ, a protein kinase involved in the devel-
opment and function of Th17 cells [52], Th2 cells [53], Tregs [54] and type 2 innate lymphoid
cells [55]; NOD2, an intracellular pattern recognition receptor that upon activation by bacterial
peptidoglycans [56] and viruses [57] promotes host defense through the production of inflam-
matory mediators [58–60]; SMAD4, a central regulator of TGF-beta signaling [61], involved in
Th2 cytokine production [62], Treg [63] and Th17 differentiation [64], the expression of selec-
tin ligands [65] and of the pro-allergic cytokine IL-9 [66]; ABCA7, a transporter protein that
moves lipids across membranes [67], enhances phagocytosis of apoptotic cells by macrophages
[68], promotes NKT cell development and function [69], and was suggested to play a role in
keratinocyte differentiation [70]; and UBE2L3, an essential component of the post-transla-
tional protein ubiquitination pathway, which plays a major role in the regulation of inflamma-
tory responses [71–75].
The combined age-of-onset phenotype analysed did not take into account information
from food allergy, as this was not available in the UK Biobank study. To partly address this lim-
itation, we tested if the 76 sentinel variants identified in the age-of-onset or multivariate
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GWAS were also associated with food allergy, both in children and adults. After correcting for
multiple testing, nine variants were significantly associated with food allergy confirmed by oral
challenge in young children of the GOFA study [15], including one variant located in a locus
not previously reported in food allergy GWAS: rs8056255 near CYLD. As such, this variant
represents a putative novel risk factor for food allergy, which should be studied in greater detail
in future studies. On the other hand, there was no evidence that the sentinel variants for age-
of-onset identified in our study were associated with food allergies (based on hospital admis-
sions) in adults of the GERA cohort. The lack of agreement between the food allergy results
obtained in the GOFA and GERA studies raises the possibility that genetic risk factors for food
allergy in children and adults might be largely distinct, which warrants further investigation.
Another potential limitation of our study is that age-of-onset reported by UK Biobank par-
ticipants may have been affected by recall bias. For example, individuals with current disease
symptoms at the time of data collection might have recalled early onset of disease more reliably
than those who no longer suffered from allergies. We addressed this potential limitation by
testing the association between the 50 sentinel variants identified in the age-of-onset GWAS in
a subset of UK Biobank individuals who reported developing asthma as a child, specifically up
to age 19. We found that the association between the 50 sentinel variants and age-of-onset in
this smaller but more homogenous group of allergic disease cases was consistent with results
obtained in the overall sample. Furthermore, we also found consistent associations when con-
sidering asthma onset recorded in children from the independent and prospective Avon Lon-
gitudinal Study of Parents and Children (ALSPAC) birth cohort. Similar results were observed
for the 26 sentinel variants identified in the multivariate GWAS (S14 Table). Therefore, the 76
sentinel variants reported in our study show a consistent pattern of association with allergic
disease age-of-onset in two analyses for which recall bias was not a major concern. Similarly,
we found that phenotypic misclassification amongst individuals who reported late onset of
allergic disease, if present, was unlikely to have significantly affected our main findings. In
addition, the collection of information in adulthood is likely to have caused overrepresentation
of SNPs involved in persistent disease and underrepresentation of association related to disease
that remitted earlier in life (transient disease). Finally, we showed that in a subset of cases that
provided data on two different occasions 4–7 years apart, age of onset of asthma was within 5
years in 86% of cases. However, we were not able to investigate this reliability for eczema and
hayfever separately, since only a combined question was available. Furthermore, we acknowl-
edge that only 3% of asthmatics in UKBB provided data on two different occasions. Thus,
recall bias may have reduced our power, but not have resulted in spurious results.
In conclusion, we show that novel risk loci for allergic disease can be identified by extending
the analytical approach that we reported recently [22] to the analysis of age-of-onset of asthma,
hay fever and eczema. GWAS of other complex diseases might also benefit from considering
age-of-onset information. We found 76 specific genetic associations with allergic disease, of
which 28 had not previously been reported. We implicate 81 genes as likely targets of the associ-
ated variants and provide further evidence that individuals with early disease onset have a
greater burden of genetic risk factors for allergic disease than individuals with late disease onset.
Methods
Definition of the combined age-of-onset phenotype and allergic disease
status
We created a single age-of-onset phenotype for individuals from the UK Biobank study [76]
that considered information from asthma, hay fever and eczema. Age-of-onset for food allergy
was not available in the UK Biobank study and so was not considered in our analysis.
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Specifically, we extracted information from two data fields included in the touchscreen
questionnaire. Field 3786, which asked “What was your age when the asthma was first diag-
nosed?”, and field 3761, which asked “What was your age when the hayfever, rhinitis or
eczema was first diagnosed?”. After excluding individuals who were not genotyped (absent
from the array data), non-missing information was available for 50,109 and 98,161 individuals,
respectively for fields 3786 and 3761. The combined age-of-onset phenotype corresponded to
the earliest age reported across these two fields, which was obtained for 127,382 individuals. Of
these, we restricted our analysis to individuals who were determined to suffer from at least one
allergic disease (asthma and/or hay fever and/or eczema) based on the criteria described in
detail previously [22]. Briefly, “asthma cases” were those with (i) both a report of “Asthma” in
field 6152 (self-reported medical conditions, specifically the question “Has a doctor ever told
you that you have had any of the following conditions?”) and a code for asthma in field 20002
(verbal interview), or alternatively, an ICD10 code for asthma in fields 41202 (Diagnoses–
main ICD10) or 41204 (Diagnoses–secondary ICD10); and (ii) no report of COPD in fields
6152 or 20002, nor of other respiratory diseases in field 20002. “Hay fever/eczema cases” were
those who answered “Hay fever, allergic rhinitis or eczema” in field 6152. Lastly, allergic dis-
ease cases were individuals who were classified as an “asthma case” and/or “hay fever/eczema
case”, a total of 124,616 individuals.
To identify individuals who suffered from a single allergic disease, we had to classify hay
fever and eczema status separately, which could not be determined using field 6152 per se
(“Has a doctor ever told you that you have had any of the following conditions?”). This is
because of the seven possible answers to this question, a single item covered the two different
diseases, specifically the answer “Hayfever, allergic rhinitis or eczema”. To identify individuals
who reported suffering specifically from hay fever, we instead considered information reported
in the verbal interview (field 20002) and ICD10 codes (fields 41202 and 41204), as described
above for asthma. This information was available for a subset of individuals who answered
“Hayfever, allergic rhinitis or eczema” in field 6152. We then used the exact same approach
(i.e. information from fields 20002, 41202 and 41204) to identify “eczema cases”.Using this
approach, we were able to classify hay fever and eczema status separately, in addition to
asthma, for 52,114 individuals. Of these, 975 suffered from all three diseases, 8,172 from two
diseases and 42,967 from a single disease. Of the latter, 23,375 reported suffering from asthma
only; 15,445 from hay fever only; and 4,147 from eczema only.
Association analysis of the combined age-of-onset phenotype
We first performed multi-dimensional scaling (MDS) analysis of allele sharing to identify indi-
viduals who clustered closely to Europeans of the 1000 Genomes project, as described previ-
ously [22]. Of the 124,616 individuals with a phenotype available for analysis, 117,530 clustered
within 5 standard deviations of the mean for the first and second MDS components estimated
using individuals from the five European ancestry groups (CEU, GBR, FIN, IBS and TSI) of the
1000 Genomes project. As such, these individuals were considered to have European ancestry
and were retained for analysis. We then excluded 400 individuals who: (i) had self-reported sex
different from genetically-inferred sex; (ii) were outliers when considering genotype missing
rates and/or genome-wide heterozygosity levels; (iii) had more than 10 third degree relatives or
were excluded from kinship inference; and/or (iv) were not present in the imputed dataset
released in July 2017. The first three criteria were assessed based on information included in the
QC file ukb_sqc_v2.txt released by the UK Biobank study. After these exclusions, phenotype
and genotype data were available for 117,130 individuals. Of these, 22,029 reported suffering
from asthma only; 14,474 from hay fever only; and 3,939 from eczema only.
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To maximize power, we did not select a subset of unrelated individuals for analysis but
instead tested variants for association with age-of-onset using the linear mixed model imple-
mented in BOLT-LMM [77], which includes a genetic relationship matrix (GRM) as a random
effect in the model. The GRM was estimated based on 577,110 array SNPs obtained after qual-
ity control filters, namely a minor allele frequency (MAF) >1%, call rate>95% and Hardy-
Weinberg equilibrium P-value>10−6. Age-of-onset was quantile-normalized prior to analysis;
gender and an indicator of the genotyping array used were included as discrete covariates.
Of the 92 million variants with imputed data released by the UK Biobank, we analysed
7,647,814 variants that (i) had a MAF >1%; (ii) were imputed based on the Haplotype Refer-
ence Consortium panel; (iii) had matching alleles when compared to genotype data from the
1000 Genomes project; and (iv) had a unique reference sequence (rs) number and genomic
position (based on hg19). We used a P-value threshold of 3x10-8 for genome-wide significance,
as suggested for studies that analyse variants with a MAF >1% [78].
Identification of variants with a statistically independent association with
the combined age-of-onset phenotype
We used the approximate joint association analysis option of GCTA [79] to identify variants
that remained associated with age-of-onset at a P<3x10-8 after accounting for the effects of
nearby (<10 Mb) more strongly associated variants. In this analysis, LD was estimated based
on a subset of 5,000 unrelated allergic disease cases from the UK Biobank study.
Association analysis of age-of-onset in individuals suffering from a single
allergic disease
To understand if variants discovered through the analysis of the combined age-of-onset phe-
notype were likely to influence the age-of-onset of the three individual diseases considered
(asthma, hay fever and eczema), we performed association analyses in adult cases from the UK
Biobank study who reported suffering from a single allergic disease, as described in detail pre-
viously [22].
Specifically, we tested the association between selected variants and age-of-onset separately
in three non-overlapping groups of individuals who suffered from a single allergic disease:
asthma only cases (n = 22,029), hay fever only cases (n = 14,474), and eczema only cases
(n = 3,969). These sample sizes are smaller than indicated above (23,375, 15,445 and 4,147,
respectively) because individuals of non-European ancestry were not included in the associa-
tion analysis. For each SNP, we then compared the effect on age-of-onset (i.e. beta from the
linear model) between individual diseases (i.e. asthma vs. hay fever, asthma vs. eczema and hay
fever vs. eczema), using the formula z = sigma / SE_sigma, where sigma = beta_diseaseA–
beta_diseaseB, and SE_sigma = sqrt(SE_beta_diseaseA^2 + SE_beta_diseaseB^2), which fol-
lows a normal distribution.
Association between age-of-onset sentinel variants and allergic disease risk
We recently observed that many variants associated with the case-control status of allergic dis-
ease–defined by the presence of asthma, hay fever and/or eczema–were also associated with
variation in age-of-onset amongst allergic disease cases [22]. We therefore reasoned that the
reverse would also be likely: that many variants associated with variation in age-of-onset
would be associated with disease liability, as suggested by Sarnowski et al. [29]. To test this, for
each variant with a genome-wide significant association with age-of-onset in the analysis
described above, we extracted association results from our recent GWAS of allergic disease
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[22]; after excluding overlapping samples (the UK Biobank study, n = 138,354), results were
based on the analysis of 222,484 individuals, which included 137,883 cases with asthma and/or
hay fever and/or eczema, and 84,601 disease-free controls. If a variant of interest was not
directly tested in that GWAS, we extracted results for the most correlated proxy (with r2>0.8),
if available.
Genetic correlation between age-of-onset and disease case-control status
To understand the extent to which the same genetic variants contribute to variation in disease
age-of-onset and disease liability, we applied LD-score regression [32] to the association sum-
mary statistics obtained in the GWAS of the combined age-of-onset phenotype carried out as
part of this study (n = 117,130) and in the GWAS of a combined allergic disease case-control
phenotype (n = 360,838) that we reported recently [22]. The genetic correlation between the
two GWAS (which is not biased by sample overlap) was estimated based on 1.1 million Hap-
Map 3 SNPs, all with a MAF>1%, as recommended previously [32].
To illustrate graphically the observed genetic correlation between disease liability and age-
of-onset, we compared the age-of-onset between individuals with a high and low polygenic
burden of allergic disease risk SNPs. Specifically, for each individual in the UK Biobank study,
we calculated a polygenic risk score (PRS) as the weighted average of the number of disease-
predisposing alleles across the 136 sentinel variants that we identified in our recent GWAS of
allergic disease case-control status [22]. Weights for each SNP corresponded to the allelic effect
(i.e. beta) reported in that GWAS [22]. We then restricted our analysis to individuals that
reported suffering from a single disease, as described above: asthma only cases (n = 22,029),
hay fever only cases (n = 14,474), and eczema only cases (n = 3,969). Within each of these case
groups, we identified individuals with a PRS in the top 10% and bottom 10% for that group,
and then compared the distribution of age-of-onset between the two PRS groups using
descriptive statistics.
Multivariate GWAS of allergic disease age-of-onset and case-control status
If two phenotypes have a genetic correlation that is significantly different from 0, then multi-
variate association analysis could potentially increase the power to identify variants that con-
tribute to the heritability of both phenotypes, when compared to the alternative of testing each
phenotype separately. Whether or not increased power is obtained with a multivariate test
depends, for example, on the statistical approach used, the magnitude of the overall phenotypic
correlation between the two phenotypes, as well as the magnitude and direction of the effect of
the shared variant on the two phenotypes [33,80,81]. To analyse the joint association between
single SNPs and allergic disease age-of-onset and case-control status, we used the recently
described metaUSAT approach [33], for three main reasons. First, this approach is applicable
to summary statistics from GWAS with unknown sample overlap. Second, it accommodates
summary statistics from a mix of continuous and binary traits. And third, by combining two
classes of tests (MANOVA and sum squared score tests), metaUSAT provides increased power
over alternative methods when a SNP affects all phenotypes analysed [33]. MetaUSAT was
applied to the summary statistics of the combined age-of-onset phenotype carried out as part
of this study (n = 117,130) and the GWAS of a combined allergic disease case-control pheno-
type (n = 360,838) that we reported recently [22]. Because we were interested in identifying
SNPs that were genome-wide significant (i.e. with P<3x10-8) in the multivariate but not in the
separate univariate analyses, we first used approximate conditional analyses [79] to adjust the
results from each GWAS for the effects of variants that had a statistically independent associa-
tion at P<3x10-8 in the respective study (which were identified by the joint association analysis
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described above). After this adjustment, no single SNP had a P<3x10-8 in each of the two indi-
vidual phenotype GWAS as expected. MetaUSAT was then applied to the adjusted GWAS; the
Pearson correlation coefficient between z-scores of the two phenotypes was estimated based
on SNPs not associated with either trait (i.e. with a P>0.05 for both).
A new multivariate test of association with similar properties to metaUSAT (e.g. applicable
to summary statistics of GWAS with sample overlap), was reported just prior to the submis-
sion of this manuscript for publication–the MTAG approach [34]. We therefore tested if the
multivariate associations discovered with metaUSAT were also supported by results from this
different approach. For each SNP, instead of a multivariate P-value, MTAG returns an effect
estimate (beta, SE and P-value) for each phenotype that incorporates information contained in
the GWAS of the other phenotype. This increases the effective sample size of each analysis and
so it improves the power to detect associations with variants that are shared between the two
phenotypes [34].
Sentinel variants not previously implicated in the aetiology of allergic
disease
To determine if a sentinel variant was in LD with a SNP previously reported to associate with
any allergic disease, we (i) identified all SNPs in LD (r2>0.05) with that sentinel variant, using
genotype data from individuals of European descent from the 1000 Genomes Project [82]
(n = 294, release 20130502_v5a); and (ii) determined if the sentinel variant or any of the corre-
lated SNPs identified were reported to associate with any allergic disease (asthma, hay fever,
eczema, food allergy or atopy) in the NHGRI-EBI GWAS catalog database [83], which was
downloaded on the 10th of January 2018. This catalogue was supplemented with recent studies
not included at the time of submission of this manuscript. [2, 31, 84].
Predicting target genes of sentinel variants based on LD with eQTL and
non-synonymous SNPs
We performed the following steps to identify genes for which variation in gene expression
and/or protein sequence was associated with sentinel SNPs identified in the age-of-onset and
multivariate GWAS.
First, we identified single nucleotide polymorphisms (SNPs) associated with variation in
gene expression (i.e. expression quantitative trait loci (eQTL)) in published transcriptome
studies of five broad tissue types relevant for allergic disease: individual immune cell types,
lung, skin, spleen and whole-blood. We identified a total of 43 transcriptome studies reporting
results from eQTL analyses in any one of those five tissue types (S1 Table). Some studies
included multiple cell types, experimental conditions and/or eQTL types, resulting in a total of
101 separate eQTL datasets. For each eQTL dataset, we then (i) downloaded the original publi-
cation tables/files containing results for the eQTL reported; (ii) extracted the SNP identifier,
gene name, association P-value and directional effect (if available; beta/z-score and effect
allele); (iii) excluded eQTL located >1 Mb of the respective gene (i.e. trans eQTL), because
often these are thought to be mediated by cis effects [85]; (iv) excluded eQTL with an associa-
tion P>8.9x10-10, a conservative threshold that corrects for 55,765 genes (based on GENCODE
v19), each tested for association with 1,000 SNPs (as suggested by others [86–88]); and (v) for
each gene, used the—clump procedure in PLINK [89] to reduce the list of eQTL identified
(which often included many correlated SNPs) to a set of ‘sentinel eQTL’, defined as the SNPs
with strongest association with gene expression and in low LD (r2<0.05, linkage disequilib-
rium (LD) window of 2 Mb) with each other.
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Second, we identified genes for which a sentinel eQTL reported in any of the 101 eQTL
datasets described above was in high LD (r2>0.8) with a sentinel variant identified in the age-
of-onset or multivariate GWAS. That is, we only considered genes for which there was high
LD between a sentinel eQTL and a sentinel allergic disease variant, which reduces the chance
of spurious co-localization.
Third, we used wANNOVAR [90] to identify genes containing non-synonymous SNPs
amongst all variants in LD (r2>0.8) with any sentinel variants. SNPs in LD with sentinel vari-
ants were identified using genotype data from individuals of European descent from the 1000
Genomes Project [83] (n = 294, release 20130502_v5a).
Association between sentinel variants and the risk of food allergy
Age-of-onset of food allergy was not available in the UK Biobank study and so it was not con-
sidered in our combined allergic disease phenotype. To partly address this limitation, we deter-
mined if variants identified in the age-of-onset or multivariate analysis also contribute to food
allergy risk. Specifically, we extracted association results for selected variants from a GWAS of
food allergy conducted in the GOFA cohort that we published recently [15], which included
497 children with a positive oral food challenge and 2,387 controls (the genomic inflation fac-
tor [λ] for this GWAS was 1.03). All cases were recruited at the time of diagnosis (mean age
2.1; 84% under the age of 4). The most common food allergy was observed with hen’s egg
(58%), followed by peanut (44%) and cow’s milk (34%). To study the association between each
variant and food allergy in adults, we extracted association results from a GWAS of food
allergy conducted in the GERA cohort, which we also reported recently [16], including 1,104
adults with an ICD9 (i.e. hospital admission) code for food allergy and 23,945 controls. The
genomic inflation factor for this GWAS was 1.01. Most cases were admitted to hospital because
of an allergic reaction to fish/shellfish (58%), peanuts (16%), eggs (13%) or milk (8%).
This study was approved by the Human Ethics Committee of the QIMR Berghofer Medical
Research Institute. Approval of individual studies has been reported in Ferreira et al. [22].
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